Literature DB >> 3733527

Elsamicins, new antitumor antibiotics related to chartreusin. I. Production, isolation, characterization and antitumor activity.

M Konishi, K Sugawara, F Kofu, Y Nishiyama, K Tomita, T Miyaki, H Kawaguchi.   

Abstract

New antitumor antibiotics, elsamicins A and B, were isolated from the culture broth of an unidentified actinomycete strain J907-21 (ATCC 39417). They are structurally related to chartreusin, containing the common aglycone, chartarin, but contain different sugar moieties. Elsamicin A, the major component, has an amino sugar in the molecule which makes the antibiotic much more water-soluble than chartreusin. Elsamicin A exhibits strong inhibitory activity against various murine tumors including leukemia P388, leukemia L1210, and melanoma B16 but elsamicin B which lacks the amino sugar showed only marginal activity. The potency of elsamicin A was 10-30 times more potent than that of chartreusin in terms of minimum effective dose.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3733527     DOI: 10.7164/antibiotics.39.784

Source DB:  PubMed          Journal:  J Antibiot (Tokyo)        ISSN: 0021-8820            Impact factor:   2.649


  5 in total

1.  Thermodynamic characterization of the multivalent binding of chartreusin to DNA.

Authors:  Francisca Barceló; Damiana Capó; José Portugal
Journal:  Nucleic Acids Res       Date:  2002-10-15       Impact factor: 16.971

2.  Validated HPLC procedures for the analysis of MBY-28090 in human plasma and urine.

Authors:  R C Gaver; G Deeb; A M George
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

Review 3.  A comprehensive review of glycosylated bacterial natural products.

Authors:  Sherif I Elshahawi; Khaled A Shaaban; Madan K Kharel; Jon S Thorson
Journal:  Chem Soc Rev       Date:  2015-11-07       Impact factor: 54.564

4.  Phase II study of elsamitrucin (BMY-28090) for the treatment of patients with refractory/relapsed non-Hodgkin's lymphoma.

Authors:  S L Allen; L P Schacter; S M Lichtman; R Bukowski; D Fusco; M Hensley; P O'Dwyer; A Mittelman; B Rosenbloom; S Huybensz
Journal:  Invest New Drugs       Date:  1996       Impact factor: 3.850

5.  Experimental antitumor activity of BMY-28090, a new antitumor antibiotic.

Authors:  J E Schurig; W T Bradner; G A Basler; W C Rose
Journal:  Invest New Drugs       Date:  1989-07       Impact factor: 3.850

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.